Sarepta Therapeutics
Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy
August 4, 2025Research and Development Duchenne Muscular Dystophy, Hansa Biopharma, Rare Diseases, Sarepta Therapeutics, clinical trial, genetic disorder
Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the use of imlifidase as a …
Sarepta Therapeutics gains expanded FDA approval for DMD treatment
June 21, 2024Medical Communications DMD, Musculo-skeletal disorder, Sarepta Therapeutics
Sarepta Therapeutics has announced that the US Food and Drug Administration (FDA) has approved an expansion to the labelled indication …
FDA pre-meeting report raises concerns over Sarepta’s gene therapy for Duchenne muscular dystrophy
May 11, 2023Medical Communications Duchenne Muscular Dystrophy, FDA, Musculo-skeletal disorder, Sarepta Therapeutics, gene therapy
The US Food and Drug Administration (FDA) has released a report in preparation for its 12 May decision on Sarepta …
Sarepta appoints ex-Allergan President as new CEO
June 29, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sarepta Therapeutics
Sarepta Therapeutics has announced the appointment of ex-Allergan President Doug Ingram as the company’s new CEO – it’s third in …
Weekly Movers: XenoPort, Akari, Bayer…
May 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Sarepta Therapeutics, Stick Market, Stock, Xenoport, finance
Bayer-Monsanto story comes close on the heels of Sanofi-Medivation tussle as the pharma sector goes through the motions of consolidation. …
Shares at Sarepta Therapeutics jump after FDA delay in drug approval review
May 26, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, Sarepta Therapeutics, approval, delay, delayed announcement, muscular dystrophy, sarepta, treatment
Sarepta Therapeutics (NASDAQ: SRPT) has witnessed a sharp rise in the price of its shares after the US Food and …
Shares plunge at Sarepta after negative FDA review on muscle disorder drug
April 21, 2016Research and Development, Sales and Marketing FDA, Sarepta Therapeutics, Shares, dive, fall, negative, plunge, sarepta
Sarepta Therapeutics (NASDAQ: SPRT) is counting the cost as shares plunge following a negative review given by staff at the …
US FDA sets April 25 date to review Sarepta’s DMD drug, shares jump
March 11, 2016Medical Communications, Research and Development Duchenne Muscular Dystrophy, Eteplirsen, Sarepta Therapeutics, US FDA
Shares in US-based Sarepta Therapeutics (Nasdaq: SRPT) jumped nearly 15% Thursday after the US Food and Drug Administration (FDA) said it …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
